Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The company leverages its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its molecules, referred to as INDUKINE and INDUCER molecules, are intended to activate selectively in the tumor microenvironment. The most advanced product candidates are WTX-124, a systemically delivered conditionally activated interleukin-2 (IL-2) INDUKINE molecule, and WTX-330, a systemically delivered conditionally activated interleukin-12 (IL-12) INDUKINE molecule, both being evaluated for the treatment of multiple tumor types. Werewolf Therapeutics is also developing preclinical INDUKINE candidates such as WTX-712 (IL-21), WTX-518 (IL-18), and WTX-921 (IL-10), as well as preclinical INDUCER T-cell engager candidates WTX-1011 (targeting STEAP1) and WTX-2022 (targeting CDH6). Additionally, the company has licensed the worldwide rights to develop and commercialize JZP898, a conditionally activated interferon-alpha INDUKINE molecule, to Jazz Pharmaceuticals Ireland Limited. In February 2026, Werewolf Therapeutics adopted a restructuring plan to extend its capital resources, which included a reduction in force affecting approximately 64% of its workforce, as it explores strategic alternatives to maximize stockholder value.
The company generates revenue primarily through licensing and collaboration agreements, including upfront fees, milestone payments, and reimbursement for preclinical development activities. Its global collaboration and license agreement with Jazz Pharmaceuticals Ireland Limited for JZP898 provides Jazz with exclusive global development and commercialization rights, while Werewolf Therapeutics receives reimbursement for certain preclinical work and is eligible to receive future milestone and royalty payments upon successful development and commercialization of JZP898. Werewolf Therapeutics has not yet commercialized any therapeutic product and therefore does not generate revenue from product sales; its current revenue stream is derived solely from these partnership arrangements. The company may also seek additional revenue through future collaborations, strategic partnerships, or the sale of assets as part of its ongoing strategic review process, and it continues to pursue potential funding sources to advance its clinical programs.
Werewolf Therapeutics operates in the highly competitive biopharmaceutical immunotherapy sector, where it contends with large pharmaceutical companies, specialty biotech firms, and academic institutions developing cytokines, immune checkpoint inhibitors, and T-cell engagers. Its lead product candidate WTX-124 may compete with approved IL-2 therapy Proleukin (aldesleukin) and numerous preclinical IL-2 programs from companies such as Anaveon AG, Anwita Biosciences, Ascendis Pharma, Asher Biotherapeutics, Aulos Bioscience, BioNTech SE, Cue Biopharma, DEKA Biosciences, Merck & Co., Medicenna Therapeutics, F. Hoffmann-La Roche, Synthekine, and Xilio Therapeutics. WTX-330, if approved, would face competition from other IL-12 cytokine programs in development, including those from Sanofi (Amunix), DEKA Biosciences, DragonFly Therapeutics, Juno Therapeutics (Bristol-Myers Squibb), OncoSec Medical, PDS Biotechnology, Philogen, Sonnet BioTherapeutics, Turnstone Biologics (partnered with Takeda), Xilio Therapeutics, and Zymeworks. The company’s competitive advantages stem from its proprietary PREDATOR platform, which enables conditionally activated immunomodulators designed to limit systemic toxicity, extend half-life, and selectively release active cytokines in the tumor microenvironment, thereby potentially improving the therapeutic index compared with conventional cytokine therapies. Additionally, Werewolf Therapeutics benefits from its proprietary masking technology and linker selection process, which aim to enhance tumor-specific activation while minimizing off-tumor activity, a differentiation that is not universally present among its competitors.
The company’s customer base consists primarily of pharmaceutical partners and collaborators that license its technology and product candidates, exemplified by Jazz Pharmaceuticals, which holds exclusive global rights to JZP898 and reimburses Werewolf Therapeutics for preclinical development activities. In addition, Werewolf Therapeutics anticipates serving oncology patients, hospitals, and clinics that would administer its therapeutics upon regulatory approval, although it currently lacks a direct sales or commercial infrastructure. The company may also engage with contract manufacturing organizations, clinical research organizations, and other service providers as part of its drug development and potential commercialization efforts. While no product has yet reached the market, the company’s collaborations are structured to provide revenue through licensing fees, milestone payments, and royalties, positioning its partners as the primary near-term customers.